Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. (2019)

First Author: Mehanna H
Attributed to:  MICA: The Newcastle Proximity Laboratory funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(18)32752-1

PubMed Identifier: 30449623

Publication URI: http://europepmc.org/abstract/MED/30449623

Type: Journal Article/Review

Volume: 393

Parent Publication: Lancet (London, England)

Issue: 10166

ISSN: 0140-6736